Cingulate extends CMO Matthew Brams' trial employment period to year-end 2026
A subsidiary of Cingulate Inc. amended its agreement with Chief Medical Officer Matthew N. Brams, pushing his trial employment deadline back three months.
Cingulate Inc. disclosed in an 8-K filing that on September 30, 2026, its wholly owned subsidiary Cingulate Therapeutics LLC signed a second amendment to the employment agreement covering Matthew N. Brams, who serves as Executive Vice President and Chief Medical Officer. The amendment updates the employment agreement between Brams and CTx, which had taken effect January 1, 2026.1
The change centers on timing. Under the amendment, the trial period for Brams' full-time employment was pushed back, moving the end date from September 30, 2026 to December 31, 2026.1
The filing states that the summary of the amendment is qualified in full by the actual document, which is attached as Exhibit 10.1 to the Current Report and incorporated by reference.1
Cingulate listed the amendment as Exhibit 10.1, describing it as Amendment No. 2 to the Employment Agreement, effective September 30, 2026, between Cingulate Therapeutics, LLC and Matthew N. Brams.1
The report was signed on behalf of the company by Chief Executive Officer Shane J. Schaffer, dated October 2, 2026. The filing was made under Item 5.02, which covers executive appointments and compensation arrangements, and Item 9.01, which covers financial statements and exhibits.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.